-
K.
Behringer,
V.
Diehl
(2005)
Twenty‐five years clinical trials of the German Hodgkin Study Group (GHSG)
European Journal of Haematology, 75
-
A.
Engert,
H.
Haverkamp,
C.
Kobe,
J.
Marková,
C.
Renner,
A.
Ho,
J.
Zijlstra,
Z.
Král,
M.
Fuchs,
M.
Hallek,
L.
Kanz,
H.
Döhner,
B.
Dörken,
N.
Engel,
M.
Topp,
S.
Klutmann,
H.
Amthauer,
A.
Bockisch,
R.
Kluge,
C.
Kratochwil,
O.
Schober,
R.
Greil,
R.
Andreesen,
M.
Kneba,
M.
Pfreundschuh,
H.
Stein,
H.
Eich,
R.
Müller,
M.
Dietlein,
P.
Borchmann,
V.
Diehl
(2012)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
The Lancet, 379
-
L.
Gordon,
F.
Hong,
R.
Fisher,
N.
Bartlett,
J.
Connors,
R.
Gascoyne,
H.
Wagner,
P.
Stiff,
B.
Cheson,
M.
Gospodarowicz,
R.
Advani,
B.
Kahl,
J.
Friedberg,
K.
Blum,
T.
Habermann,
J.
Tuscano,
R.
Hoppe,
S.
Horning
(2013)
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 6
-
A.
Hay,
B.
Klimm,
Bingshu
Chen,
H.
Goergen,
L.
Shepherd,
M.
Fuchs,
M.
Gospodarowicz,
P.
Borchmann,
J.
Connors,
J.
Marková,
M.
Crump,
A.
Lohri,
J.
Winter,
B.
Dörken,
R.
Pearcey,
Volker
Diehl,
S.
Horning,
H.
Eich,
A.
Engert,
R.
Meyer,
R.
Meyer
(2013)
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 12
-
D.
Hasenclever,
Volker
Diehl,
J.
Armitage,
D.
Assouline,
M.
Björkholm,
E.
Brusamolino,
G.
Canellos,
P.
Carde,
D.
Crowther,
David
Cunningham,
H.
Eghbali,
Christophe
Ferm,
R.
Fisher,
J.
Glick,
B.
Glimelius,
P.
Gobbi,
H.
Holte,
S.
Horning,
T.
Lister,
D.
Longo,
F.
Mandelli,
A.
Polliack,
S.
Proctor,
L.
Specht,
J.
Sweetenham,
G.
Hudson
(1998)
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
The New England journal of medicine, 339 21
-
B.
Tresckow,
A.
Plütschow,
M.
Fuchs,
B.
Klimm,
J.
Marková,
A.
Lohri,
Z.
Král,
R.
Greil,
M.
Topp,
J.
Meissner,
J.
Zijlstra,
M.
Soekler,
H.
Stein,
H.
Eich,
R.
Mueller,
V.
Diehl,
P.
Borchmann,
A.
Engert
(2012)
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 9
-
A.
Engert,
P.
Schiller,
A.
Josting,
R.
Herrmann,
P.
Koch,
M.
Sieber,
F.
Boissevain,
M.
Wit,
J.
Mezger,
E.
Duhmke,
N.
Willich,
R.
Muller,
B.
Schmidt,
H.
Renner,
H.
Muller-Hermelink,
B.
Pfistner,
J.
Wolf,
D.
Hasenclever,
M.
Loffler,
V.
Diehl
(2003)
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 19
-
Irk,
Asenclever,
Olker,
Iehl
(2000)
A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE
-
J.
Radford,
T.
Illidge,
N.
Counsell,
B.
Hancock,
R.
Pettengell,
P.
Johnson,
J.
Wimperis,
D.
Culligan,
B.
Popova,
Paul
Smith,
A.
McMillan,
A.
Brownell,
A.
Kruger,
A.
Lister,
P.
Hoskin,
M.
O'Doherty,
S.
Barrington
(2015)
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
The New England journal of medicine, 372 17
-
M.
Kedmi,
A.
Apel,
T.
Davidson,
I.
Levi,
E.
Dann,
A.
Polliack,
I.
Ben-bassat,
A.
Nagler,
A.
Avigdor
(2015)
High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan
Acta Haematologica, 135
-
A.
Engert,
V.
Diehl,
J.
Franklin,
A.
Lohri,
B.
Dörken,
W.
Ludwig,
P.
Koch,
M.
Hänel,
M.
Pfreundschuh,
M.
Wilhelm,
L.
Trümper,
W.
Aulitzky,
M.
Bentz,
M.
Rummel,
O.
Sezer,
H.
Müller-hermelink,
D.
Hasenclever,
M.
Löffler
(2009)
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
-
M.
Schaapveld,
B.
Aleman,
Anna
Eggermond,
C.
Janus,
A.
Krol,
R.
Maazen,
J.
Roesink,
J.
Raemaekers,
J.
Boer,
J.
Zijlstra,
G.
Imhoff,
E.
Petersen,
P.
Poortmans,
M.
Beijert,
M.
Lybeert,
I.
Mulder,
O.
Visser,
M.
Louwman,
I.
Krul,
P.
Lugtenburg,
F.
Leeuwen
(2015)
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.
The New England journal of medicine, 373 26
-
M.
Ch
(2015)
Early FDG-PET Adapted Treatment Improves the Outcome of Early FDG-PET-Positive Patients With Stages I/II Hodgkin Lymphoma (HL): Final Results of the Randomized Intergroup EORTC/LYSA/FIL H10 Trial.
Clinical advances in hematology & oncology : H&O, 13 8 Suppl 9
-
A.
Engert,
A.
Plütschow,
H.
Eich,
A.
Lohri,
B.
Dörken,
P.
Borchmann,
B.
Berger,
R.
Greil,
K.
Willborn,
M.
Wilhelm,
J.
Debus,
M.
Eble,
M.
Sökler,
A.
Ho,
A.
Rank,
A.
Ganser,
L.
Trümper,
C.
Bokemeyer,
H.
Kirchner,
J.
Schubert,
Z.
Král,
M.
Fuchs,
H.
Müller-hermelink,
R.
Müller,
V.
Diehl
(2010)
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
The New England journal of medicine, 363 7
-
R.
Meyer,
M.
Gospodarowicz,
J.
Connors,
R.
Pearcey,
W.
Wells,
J.
Winter,
S.
Horning,
A.
Dar,
C.
Shustik,
D.
Stewart,
M.
Crump,
M.
Djurfeldt,
Bingshu
Chen,
L.
Shepherd
(2012)
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
The New England journal of medicine, 366 5
-
P.
Zinzani,
A.
Broccoli,
D.
Gioia,
A.
Castagnoli,
G.
Ciccone,
A.
Evangelista,
A.
Santoro,
U.
Ricardi,
M.
Bonfichi,
E.
Brusamolino,
G.
Rossi,
A.
Anastasia,
F.
Zaja,
U.
Vitolo,
V.
Pavone,
A.
Pulsoni,
L.
Rigacci,
G.
Gaidano,
C.
Stelitano,
F.
Salvi,
C.
Rusconi,
M.
Tani,
R.
Freilone,
P.
Pregno,
E.
Borsatti,
G.
Sacchetti,
L.
Argnani,
A.
Levis
(2016)
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 12
-
J.
Marková,
D.
Kahraman,
C.
Kobe,
M.
Skopalová,
H.
Mociková,
K.
Klásková,
K.
Dědečková,
H.
Eich,
B.
Böll,
M.
Dietlein,
T.
Kozák
(2012)
Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone
Leukemia & Lymphoma, 53
-
R.
Advani,
F.
Hong,
R.
Fisher,
N.
Bartlett,
K.
Robinson,
R.
Gascoyne,
H.
Wagner,
P.
Stiff,
B.
Cheson,
D.
Stewart,
L.
Gordon,
B.
Kahl,
J.
Friedberg,
K.
Blum,
T.
Habermann,
J.
Tuscano,
R.
Hoppe,
S.
Horning
(2015)
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
-
P.
Ganesan,
R.
Rajendranath,
K.
Kannan,
V.
Radhakrishnan,
T.
Ganesan,
Karthik
Udupa,
K.
Lakshmipathy,
V.
Mahajan,
S.
Sundersingh,
S.
Rajaraman,
R.
Krishnakumar,
TG
Sagar
(2015)
Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 26 6
-
F.
Zallio,
S.
Tamiazzo,
C.
Monagheddu,
F.
Merli,
F.
Ilariucci,
C.
Stelitano,
A.
Liberati,
D.
Mannina,
U.
Vitolo,
E.
Angelucci,
D.
Scalabrini,
D.
Vallisa,
M.
Bellei,
A.
Bari,
G.
Ciccone,
F.
Salvi,
A.
Levis
(2016)
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)
British Journal of Haematology, 172
-
Yinfei
Kong,
Pouya
Khankhanian,
D.
Himmelstein,
A.
Hwang,
K.
Rand,
Dalin
Li,
D.
Berg,
A.
Diepstra,
D.
Conti,
S.
Bhatia,
P.
Gourraud,
S.
Glaser,
T.
Mack,
J.
Oksenberg,
K.
Onel,
A.
Berg,
R.
Jarrett,
J.
Mckay,
H.
Hjalgrim,
S.
Baranzini,
F.
Gilliland,
W.
Gauderman,
W.
Cozen
(2014)
Meta-Analysis of Hodgkin Lymphoma and Asthma Genome-Wide Association Scans reveals common variants in GATA3
Blood, 124
-
O.
Press,
Hongli
Li,
H.
Schöder,
D.
Straus,
C.
Moskowitz,
M.
LeBlanc,
L.
Rimsza,
N.
Bartlett,
A.
Evens,
E.
Mittra,
A.
LaCasce,
J.
Sweetenham,
P.
Barr,
M.
Fanale,
M.
Knopp,
A.
Noy,
E.
Hsi,
J.
Cook,
M.
Lechowicz,
R.
Gascoyne,
J.
Leonard,
B.
Kahl,
B.
Cheson,
R.
Fisher,
J.
Friedberg
(2016)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 17
-
A.
Evens,
F.
Hong,
L.
Gordon,
R.
Fisher,
N.
Bartlett,
J.
Connors,
R.
Gascoyne,
H.
Wagner,
M.
Gospodarowicz,
B.
Cheson,
P.
Stiff,
R.
Advani,
T.
Miller,
R.
Hoppe,
B.
Kahl,
S.
Horning
(2013)
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
British Journal of Haematology, 161
-
A.
Evens,
I.
Helenowski,
E.
Ramsdale,
C.
Nabhan,
R.
Karmali,
B.
Hanson,
B.
Parsons,
Scott
Smith,
A.
Larsen,
J.
McKoy,
B.
Jovanovic,
S.
Gregory,
L.
Gordon,
Sonali
Smith
(2012)
A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
Blood, 119 3
-
B.
Böll,
H.
Goergen,
K.
Behringer,
P.
Bröckelmann,
F.
Hitz,
A.
Kerkhoff,
R.
Greil,
B.
Tresckow,
D.
Eichenauer,
C.
Buerkle,
S.
Borchmann,
M.
Fuchs,
V.
Diehl,
A.
Engert,
P.
Borchmann
(2016)
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
Blood, 127 18
-
K.
Behringer,
K.
Breuer,
T.
Reineke,
M.
May,
L.
Nogova,
B.
Klimm,
Tatiana
Schmitz,
L.
Wildt,
V.
Diehl,
A.
Engert
(2005)
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
-
J.
Radford,
D.
Longo
(2015)
Second Cancers after Treatment for Hodgkin's Lymphoma--Continuing Cause for Concern.
The New England journal of medicine, 373 26
-
(2014)
Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management
-
N.
Skoetz,
S.
Trelle,
M.
Rancea,
H.
Haverkamp,
V.
Diehl,
A.
Engert,
P.
Borchmann
(2013)
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
The Lancet. Oncology, 14 10
-
A.
Biggi,
A.
Gallamini,
S.
Chauvie,
M.
Hutchings,
L.
Kostakoglu,
M.
Gregianin,
M.
Meignan,
B.
Małkowski,
M.
Hofman,
S.
Barrington
(2013)
International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
The Journal of Nuclear Medicine, 54
-
L.
Murray,
B.
Sethugavalar,
H.
Robertshaw,
E.
Bayman,
E.
Thomas,
D.
Gilson,
R.
Prestwich
(2015)
Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Clinical oncology (Royal College of Radiologists (Great Britain)), 27 7
-
V.
Ballová,
J.
Rüffer,
H.
Haverkamp,
B.
Pfistner,
H.
Müller-hermelink,
E.
Dühmke,
P.
Worst,
M.
Wilhelmy,
R.
Naumann,
M.
Hentrich,
H.
Eich,
A.
Josting,
M.
Löffler,
V.
Diehl,
A.
Engert
(2005)
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).
Annals of oncology : official journal of the European Society for Medical Oncology, 16 1
-
B.
Klimm,
H.
Goergen,
M.
Fuchs,
B.
Tresckow,
B.
Böll,
J.
Meissner,
A.
Glunz,
Volker
Diehl,
H.
Eich,
A.
Engert,
P.
Borchmann
(2013)
Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 12
-
Charles
Mesguich,
A.
Cazeau,
K.
Bouabdallah,
P.
Soubeyran,
M.
Guyot,
N.
Milpied,
L.
Bordenave,
E.
Hindié
(2016)
Hodgkin lymphoma: a negative interim‐PET cannot circumvent the need for end‐of‐treatment‐PET evaluation
British Journal of Haematology, 175
-
H.
Eich,
V.
Diehl,
H.
Görgen,
T.
Pabst,
J.
Marková,
J.
Debus,
A.
Ho,
B.
Dörken,
A.
Rank,
A.
Grosu,
T.
Wiegel,
J.
Karstens,
R.
Greil,
N.
Willich,
H.
Schmidberger,
H.
Döhner,
P.
Borchmann,
H.
Müller-hermelink,
R.
Müller,
A.
Engert
(2010)
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 27
-
Kathrin
Bauer,
N.
Skoetz,
I.
Monsef,
A.
Engert,
C.
Brillant
(2011)
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
The Cochrane database of systematic reviews, 8
-
A.
Avigdor,
S.
Bulvik,
I.
Levi,
E.
Dann,
N.
Shem-Tov,
G.
Perez‐Avraham,
A.
Shimoni,
A.
Nagler,
I.
Ben-bassat,
A.
Polliack
(2010)
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 1
-
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
-
V.
Nguyen,
P.
Pophali,
Judy
Tsai,
D.
Jagadeesh,
R.
Dean,
B.
Pohlman,
D.
Morgan,
J.
Greer,
Mitchell
Smith,
B.
Hill,
N.
Reddy
(2017)
Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning
British Journal of Haematology, 179
-
J.
Raemaekers,
M.
André,
M.
Federico,
T.
Girinsky,
R.
Oumedaly,
E.
Brusamolino,
P.
Brice,
C.
Fermé,
R.
Maazen,
M.
Gotti,
R.
Bouabdallah,
C.
Sebban,
Y.
Lievens,
A.
Re,
A.
Stamatoullas,
F.
Morschhauser,
P.
Lugtenburg,
E.
Abruzzese,
P.
Olivier,
R.
Casasnovas,
G.
Imhoff,
T.
Raveloarivahy,
M.
Bellei,
Thierry
Borght,
S.
Bardet,
A.
Versari,
M.
Hutchings,
M.
Meignan,
C.
Fortpied
(2014)
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 12
-
M.
André,
T.
Girinsky,
M.
Federico,
O.
Reman,
C.
Fortpied,
M.
Gotti,
O.
Casasnovas,
P.
Brice,
R.
Maazen,
A.
Re,
V.
Edeline,
C.
Fermé,
G.
Imhoff,
F.
Merli,
R.
Bouabdallah,
C.
Sebban,
L.
Specht,
A.
Stamatoullas,
R.
Delarue,
V.
Fiaccadori,
M.
Bellei,
T.
Raveloarivahy,
A.
Versari,
M.
Hutchings,
M.
Meignan,
J.
Raemaekers
(2017)
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 16
-
S.
Barrington,
A.
Kirkwood,
A.
Franceschetto,
M.
Fulham,
T.
Roberts,
H.
Almquist,
E.
Brun,
K.
Hjorthaug,
Z.
Viney,
L.
Pike,
M.
Federico,
S.
Luminari,
J.
Radford,
J.
Trotman,
A.
Fosså,
L.
Berkahn,
D.
Molin,
F.
d'Amore,
D.
Sinclair,
Paul
Smith,
M.
O'Doherty,
L.
Stevens,
P.
Johnson
(2016)
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.
Blood, 127 12
-
K.
Behringer,
H.
Goergen,
F.
Hitz,
J.
Zijlstra,
R.
Greil,
J.
Marková,
S.
Sasse,
M.
Fuchs,
M.
Topp,
M.
Soekler,
S.
Mathas,
J.
Meissner,
M.
Wilhelm,
P.
Koch,
H.
Lindemann,
E.
Schalk,
R.
Semrau,
J.
Kříž,
T.
Vieler,
M.
Bentz,
E.
Lange,
R.
Mahlberg,
A.
Hassler,
M.
Vogelhuber,
D.
Hahn,
J.
Mezger,
S.
Krause,
N.
Skoetz,
B.
Böll,
B.
Tresckow,
V.
Diehl,
M.
Hallek,
P.
Borchmann,
H.
Stein,
H.
Eich,
A.
Engert
(2015)
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
The Lancet, 385
-
A.
Hay,
B.
Klimm,
Bingshu
Chen,
H.
Goergen,
L.
Shepherd,
M.
Fuchs,
M.
Gospodarowicz,
P.
Borchmann,
J.
Connors,
J.
Marková,
M.
Crump,
A.
Lohri,
J.
Winter,
B.
Dörken,
R.
Pearcey,
V.
Diehl,
S.
Horning,
H.
Eich,
A.
Engert,
R.
Meyer
(2012)
Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone
Blood, 120
-
K.
Savage,
J.
Connors,
R.
Klasa,
P.
Hoskins,
T.
Shenkier,
R.
Gascoyne,
S.
Bhimji,
T.
Pickles,
F.
Bénard,
D.
Wilson,
L.
Sehn
(2011)
The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
A.
Bradley,
B.
Carrington,
J.
Lawrance,
W.
Ryder,
J.
Radford
(1999)
Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 8
-
P.
Johnson,
M.
Federico,
A.
Kirkwood,
A.
Fosså,
L.
Berkahn,
A.
Carella,
F.
d'Amore,
G.
Enblad,
A.
Franceschetto,
M.
Fulham,
S.
Luminari,
M.
O'Doherty,
P.
Patrick,
T.
Roberts,
G.
Sidra,
L.
Stevens,
Paul
Smith,
J.
Trotman,
Z.
Viney,
J.
Radford,
S.
Barrington
(2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
The New England journal of medicine, 374 25
-
F.
Merli,
S.
Luminari,
P.
Gobbi,
N.
Cascavilla,
C.
Mammi,
F.
Ilariucci,
C.
Stelitano,
M.
Musso,
L.
Baldini,
S.
Galimberti,
F.
Angrilli,
G.
Polimeno,
P.
Scalzulli,
A.
Ferrari,
L.
Marcheselli,
M.
Federico
(2016)
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 11
-
A.
Gallamini,
C.
Patti,
S.
Viviani,
A.
Rossi,
F.
Fiore,
F.
Raimondo,
M.
Cantonetti,
C.
Stelitano,
T.
Feldman,
P.
Gavarotti,
R.
Sorasio,
A.
Mulé,
M.
Leone,
A.
Rambaldi,
A.
Biggi,
S.
Barrington,
F.
Fallanca,
U.
Ficola,
S.
Chauvie,
A.
Gianni
(2011)
Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses
British Journal of Haematology, 152
-
ACR appropriateness criteria(R) Hodgkin lymphoma-favorable prognosis stage I and II
-
Sughosh
Dhakal,
R.
Advani,
MD
Ballas,
MD
Dabaja,
MD
Flowers,
Chul,
MD
Ha,
Mph
MD,
N.
Mendenhall,
M.
Metzger,
MD
Plastaras,
MD
Roberts,
MD
Shapiro,
Sonali,
MD
Smith,
MD
Terezakis,
M.
Winkfield,
MD
Younes,
MD
Constine
(2016)
Favorable Stage I and
-
G.
Bishop
(2015)
PET-Directed Therapy for Hodgkin's Lymphoma.
The New England journal of medicine, 373 4
-
J.
Gunther,
M.
Fanale,
J.
Reddy,
M.
Akhtari,
Grace
Smith,
C.
Pinnix,
S.
Milgrom,
Z.
Yehia,
P.
Allen,
E.
Osborne,
O.
Mawlawi,
B.
Dabaja
(2016)
Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
International journal of radiation oncology, biology, physics, 96 1
-
R.
Meyer,
R.
Hoppe
(2012)
Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.
Blood, 120 23
-
P.
Ciammella,
A.
Filippi,
G.
Simontacchi,
M.
Buglione,
B.
Botto,
M.
Mangoni,
C.
Iotti,
F.
Merli,
L.
Marcheselli,
G.
Bisi,
U.
Ricardi,
A.
Versari
(2016)
Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
The British journal of radiology, 89 1061
-
K.
Savage,
J.
Connors,
D.
Villa,
G.
Hapgood,
A.
Gerrie,
T.
Shenkier,
D.
Scott,
R.
Gascoyne,
F.
Bénard,
James
Morris,
T.
Pickles,
C.
Parsons,
Donald
Wilson,
L.
Sehn
(2015)
Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation
Blood, 126
-
L.
Rigacci,
B.
Puccini,
P.
Zinzani,
A.
Biggi,
A.
Castagnoli,
F.
Merli,
M.
Balzarotti,
C.
Stelitano,
M.
Spina,
U.
Vitolo,
V.
Stefoni,
A.
Levis,
M.
Gotti,
Sancetta
Rosaria,
S.
Maria,
A.
Bosi,
A.
Gallamini
(2015)
The prognostic value of positron emission tomography performed after two courses (INTERIM‐PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)
American Journal of Hematology, 90
-
A.
Evens,
F.
Hong,
L.
Gordon,
R.
Fisher,
N.
Bartlett,
J.
Connors,
H.
Wagner,
M.
Gospodarowicz,
B.
Cheson,
R.
Advani,
B.
Kahl,
R.
Hoppe,
S.
Horning
(2011)
Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
P.
Carde,
M.
Karrasch,
C.
Fortpied,
P.
Brice,
H.
Khaled,
O.
Casasnovas,
D.
Caillot,
I.
Gaillard,
S.
Bologna,
C.
Fermé,
P.
Lugtenburg,
F.
Morschhauser,
I.
Aurer,
B.
Coiffier,
R.
Meyer,
M.
Seftel,
M.
Wolf,
B.
Glimelius,
A.
Sureda,
N.
Mounier
(2016)
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 17
-
A.
Evens,
L.
Kostakoglu
(2014)
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Hematology. American Society of Hematology. Education Program, 2014 1